Company Management to discuss the benefits of Hemodiafiltration therapy and
Quality of Life for End-Stage Renal Disease Patients
NEW YORK, May 13 /PRNewswire-FirstCall/ -- Nephros, Inc. (Amex: NEP), a
medical device company developing and marketing products designed to
improve the quality of life for the End-Stage Renal Disease (ESRD) patient,
while addressing the critical financial and clinical needs of the care
provider, today announced that it exhibited at the XLV ERA-EDTA Congress in
Stockholm, Sweden.
Independent studies have demonstrated reductions of up to 35% in
mortality risk using hemodiafiltration (HDF) therapy in place of other
standard hemodialysis therapies. Additionally, reductions in drug
requirements, lower morbidity and lower infection rates have been
demonstrated in a range of studies substituting hemodiafiltration for
hemodialysis.
The Nephros HDF system is designed to remove a range of harmful
substances more effectively and more cost-effectively than existing ESRD
treatment methods, particularly with respect to substances known
collectively as "middle molecules." These molecules have been found to
contribute to such conditions as dialysis-related amyloidosis, carpal
tunnel syndrome, degenerative bone disease and, ultimately, mortality in
the ESRD patient. Nephros's OLpur MD and H2H technologies are currently in
pre-approval clinical trials in the U.S.
"Nephros's HDF technology represents a new standard of therapy for ESRD
patients," said Norman J. Barta, Chairman and CEO of Nephros. "Our OLpur MD
hemodiafilter series and our H2H module technologies are designed to
provide a cost-effective and user-friendly means for hospitals and clinics
to upgrade to mid-dilution HDF therapy without replacing their current
dialysis machines." The Stockholm Congress will include technical
presentations addressing various clinical performance advantages of Nephros
mid-dilution HDF therapy.
About Nephros, Inc.
Nephros, Inc., headquartered in New York, is a medical device company
developing and marketing products designed to improve the quality of life
for the End-Stage Renal Disease (ESRD) patient, while addressing the
critical financial and clinical needs of the care provider. ESRD is a
disease state characterized by the irreversible loss of kidney function.
Nephros products are sold and distributed throughout Europe and are
currently being used in over fifty clinics in Europe.
Nephros also markets a line of water filtration products, the Dual
Stage Ultrafilter (DSU) that produces biologically safe water. The
Company's patented dual stage cold sterilization Ultrafilter has the
capability to filter out bacteria and, due to its exceptional filtration
levels, filter out many viruses and parasites. The DSU is in a pilot-use
program at a major U.S. medical center and has been selected for further
development by the U.S. Marine Corps.
For more information on Nephros please visit the Company's website,
http://www.nephros.com.
Forward-Looking Statements
This news release contains certain "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995, as
amended. Such statements include statements regarding the efficacy and
intended use of the Nephros's technologies under development, the timelines
for bringing such products to market and the availability of funding
sources for continued development of such products and other statements
that are not historical facts, including statements which may be preceded
by the words "intends," "may," "will," "plans," "expects," "anticipates,"
"projects," "predicts," "estimates," "aims," "believes," "hopes,"
"potential" or similar words. For such statements, Nephros claims the
protection of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are not guarantees of future performance,
are based on certain assumptions and are subject to various known and
unknown risks and uncertainties, many of which are beyond Nephros's
control. Actual results may differ materially from the expectations
contained in the forward-looking statements. Factors that may cause such
differences include the risks that: (i) Nephros may not be able to obtain
funding if and when needed or on terms favorable to it in order to continue
operations or fund its clinical trials; (ii) Nephros may not be able to
continue as a going concern; (iii) Nephros may not be able to liquidate its
short-term investments when needed to fund its operations; (iv) Nephros may
be unable to maintain compliance with the American Stock Exchange's
continued listing standards; (v) products that appeared promising to
Nephros in research or clinical trials may not demonstrate anticipated
efficacy, safety or cost savings in subsequent pre-clinical or clinical
trials; (vi) Nephros may not obtain appropriate or necessary governmental
approvals to achieve its business plan or effectively market its products;
(vii) Nephros may encounter unanticipated internal control deficiencies or
weaknesses or ineffective disclosure controls and procedures; (viii) HDF
therapy may not be accepted in the United States and/or Nephros' technology
and products may not be accepted in current or future target markets, which
could lead to failure to achieve market penetration of Nephros' products;
(ix) Nephros may not be able to sell its ESRD therapy or water filtration
products at competitive prices or profitably; and (x) Nephros may not be
able to secure or enforce adequate legal protection, including patent
protection, for its products. More detailed information about Nephros and
the risk factors that may affect the realization of forward-looking
statements is set forth in Nephros' filings with the Securities and
Exchange Commission, including Nephros' Annual Report on Form 10-KSB filed
with the SEC for the fiscal year ended December 31, 2007. Investors and
security holders are urged to read these documents free of charge on the
SEC's web site at http://www.sec.gov. Nephros does not undertake to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
SOURCE Nephros, Inc.
 back to top
Related links:
http://www.nephros.com
CONTACT:
Eileen Sukumaran of Nephros, Inc.,
+1-212-781-5113, Eileen@nephros.com
|
